ICER estimates offer warning over NASH drug prices

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Madrigal Pharmaceuticals’ (Nasda: MDGL) resmetirom and Intercept Pharmaceuticals’ (Nasdaq: ICPT) Ocaliva (obeticholic acid) for non-alcoholic steatohepatitis (NASH).

Both products are not yet approved by the US Food and Drug Administration (FDA), and the manufacturers have not yet announced what the US prices will be if they are approved.

ICER has calculated a health-benefit price benchmark (HBPB) for resmetirom to be between $39,600 and $50,100 per year, and for obeticholic acid of between $32,600 and $40,400 per year.